作者：
Cristian P,Moiola [1]
;
Carlos,Lopez-Gil [2]
;
Silvia,Cabrera [3]
;
Angel,Garcia [4]
;
Tom,Van Nyen [5]
;
Daniela,Annibali [6]
;
Tina,Fonnes [7]
;
August,Vidal [8]
;
Alberto,Villanueva [9]
;
Xavier,Matias-Guiu [10]
;
Camilla,Krakstad [11]
;
Frédéric,Amant [12]
;
Antonio,Gil-Moreno [13]
;
Eva,Colas [14]
作者单位：
Pathological Oncology Group, Biomedical Research Institute of Lleida (IRBLLEIDA), University Hospital Arnau de Vilanova, 25198 Lleida, Spain. cmoiola@irblleida.cat.
[1]
Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, CIBERONC, 08035 Barcelona, Spain. cmoiola@irblleida.cat.
[2]
Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, CIBERONC, 08035 Barcelona, Spain. carlos.lopez@vhir.org.
[3]
Gynecological Oncology Department, Vall Hebron University Hospital, 08035 Barcelona, Spain. scabrera@vhebron.net.
[4]
Pathology Department, Vall Hebron University Hospital, 08035 Barcelona, Spain. angarcia@vhebron.net.
[5]
Department of Oncology, Gynecological Oncology, KU Leuven, 3000 Leuven, Belgium. tom.vannyen@kuleuven.be.
[6]
Department of Oncology, Gynecological Oncology, KU Leuven, 3000 Leuven, Belgium. daniela.annibali@kuleuven.be.
[7]
Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway. Tina.Fonnes@uib.no.
[8]
Department of Pathology, University Hospital of Bellvitge, Oncobell, IDIBELL, CIBERONC, L'Hospitalet del Llobregat, 08907 Barcelona, Spain. avidal@bellvitgehospital.cat.
[9]
Xenopat S.L, Business Bioincubator, Bellvitge Health Science Campus, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. avidal@bellvitgehospital.cat.
[10]
Xenopat S.L, Business Bioincubator, Bellvitge Health Science Campus, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. avillanueva@iconcologia.net.
[11]
Chemoresistance and Predictive Factors Laboratory, ProCURE, Catalan Institute of Oncology (ICO), Oncobell, IDIBELL, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. avillanueva@iconcologia.net.
[12]
Pathological Oncology Group and Department of Pathology, University Hospital Arnau de Vilanova, University of Lleida, 25198 Lleida, Spain. fjmatiasguiu.lleida.ics@gencat.cat.
[13]
University Hospital Bellvitge, IRBLLEIDA, IDIBELL, CIBERONC, 08907 Barcelona, Spain. fjmatiasguiu.lleida.ics@gencat.cat.
[14]
Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway. camilla.krakstad@med.uib.no.
[15]
Centre for Gynecologic Oncology Amsterdam (CGOA), Antoni Van Leeuwenhoek-Netherlands Cancer Institute (AvL-NKI) and University Medical Centra (UMC), 1066 CX Amsterdam, The Netherlands. frederic.amant@uzleuven.be.
[16]
Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, CIBERONC, 08035 Barcelona, Spain. agil@vhebron.net.
[17]
Gynecological Oncology Department, Vall Hebron University Hospital, 08035 Barcelona, Spain. agil@vhebron.net.
[18]
Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, CIBERONC, 08035 Barcelona, Spain. eva.colas@vhir.org.
[19]
DOI
10.3390/ijms19082431
PMID
30126113
发布时间
2021-12-04
换一批
换一批
